The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels
Abstract
Oxaliplatin, a new widely used anticancer drug, displays frequent, sometimes severe, acute sensory neurotoxicity accompanied by neuromuscular signs that look like the symptoms observed in tetany and myotonia. The whole cell patch-clamp technique was employed to investigate the oxaliplatin effects on the electrophysiological properties of short-term cultured dorsal unpaired median (DUM) neurons isolated from the CNS of the cockroach Periplaneta americana. Within the clinical concentration range, oxaliplatin (40–500 μM), applied intracellularly, decreased the amplitude of the voltage-gated sodium current resulting in a reduction of half the amplitude of the action potential. For comparison, two other platinum derivatives, cisplatin and carboplatin, were found to be ineffective at reducing the sodium current amplitude. In addition, we compared the oxaliplatin action to those of its metabolites dichloro-diaminocyclohexane platinum (dach-Cl 2-platin) and oxalate. Oxalate (500 μM) was found to be effective, like oxaliplatin, at reducing the inward sodium current amplitude, whereas dach-Cl 2-platin (500 μM) failed to change the current amplitude. Interestingly, the effect of oxalate or oxaliplatin could be mimicked by using intracellularly applied 10 mM bis-( o-aminophenoxy)- N,N,N′,N′-tetraacetic acid (BAPTA), known as chelator of calcium ions. We concluded that oxaliplatin was capable of altering the voltage-gated sodium channels through a pathway involving calcium ions probably immobilized by its metabolite oxalate. The medical interest of preventing acute neurotoxic side effects of oxaliplatin by infusing Ca 2+and Mg 2+is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00656997 · Cited by 18,436
Ionic channels of excitable membranes
(1985) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(85)90172-7 · Cited by 6,982
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond, É., Faivre, S. J., WOYNAROWSKI, J. M., & Chaney, S. G. (1998) · PubMed · Cited by 520
Jacobsen, D., & McMartin, K. E. (1986) · Medical Toxicology · doi:10.1007/bf03259846 · Cited by 490
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Self-citationGregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358
Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian Cancer
van der Hoop, R. G., Vecht, C. J., van der Burg, M. E. L., Elderson, A., Boogerd, W., Heimans, J. J., Vries, E. P., van Houwelingen, J. C., Jennekens, F. G. I., Gispen, W. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220204 · Cited by 287
Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721
Mollman, J. E., Glover, D. J., Hogan, W. M., & FURMAN, R. E. (1988) · Cancer · doi:10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a · Cited by 219
Mollman, J. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001113220210 · Cited by 163
Mauldin, S. K., Gibbons, G., Wyrick, S. D., et al. (1988) · PubMed · Cited by 50
Cited by
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy
Alcindor, T., & Beauger, N. (2011) · Current Oncology · doi:10.3747/co.v18i1.708 · Cited by 432
Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms?
Carozzi, V. A., Canta, A., & Chiorazzi, A. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.014 · Cited by 431
Metadata
- Authors
- Grolleau, F., Gamelin, L., Boisdron-Celle, M., Lapied, B., Pelhate, M., & Gamelin, E.
- Venue
- Journal of Neurophysiology
- Publisher
- American Physiological Society
- Published
- 2001-05-01
- Volume
- 85
- Issue
- 5
- Pages
- 2293-2297
- ISSN
- 0022-3077 (ISSN-L)
- 1522-1598
- OpenAlex
- W2175773713
- Cited by
- 344
- References
- 11
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.